Programmable nanoprobes for molecular imaging of cancer: toward adaptive and context-responsive diagnostics

Molecular imaging has emerged as a powerful tool for early cancer detection and real-time visualization of disease progression; however, conventional imaging probes remain limited by static signal output, suboptimal specificity, and low target-to-background ratios (typically <2-3 fold), restricting their sensitivity in complex tumor microenvironments. In recent years, stimuli-responsive nanoprobes have gained significant attention as next-generation imaging agents capable of context-responsive activation and precise signal modulation, enabling 5-20-fold signal amplification in response to specific tumor-associated stimuli. This review provides a comprehensive overview of the design principles and functional architectures of stimuli-responsive nanoprobes engineered to respond to endogenous cues such as acidic pH (∼6.5-6.8), elevated glutathione concentrations (2-10 mM), enzymatic overexpression, hypoxia (<2% O₂), and redox gradients, as well as exogenous triggers including near-infrared light (700-1000 nm), magnetic fields, and ultrasound. Emphasis is placed on activatable and switchable nano systems that enable spatiotemporal control of imaging signals, thereby improving detection sensitivity several fold compared to conventional probes. Multimodal imaging enhances diagnostic performance by integrating complementary imaging modalities that offer varying spatial resolutions, ranging from micrometer-scale optical imaging and submillimeter-resolution MRI or micro-CT to millimeter-scale nuclear imaging modalities such as PET and SPECT. Strategies involving surface engineering, biomimetic coatings, and ligand-directed targeting are also highlighted here to improve tumor accumulation efficiency (often >5-10% of injected dose per gram). In addition, the integration of artificial intelligence with nanoscale imaging systems for real-time data interpretation and adaptive diagnostics is examined. Finally, key challenges related to biocompatibility, scalability, and clinical translation are critically analyzed. Collectively, stimuli-responsive nanoprobes represent a transformative approach in molecular imaging, offering adaptive, high-precision platforms for advancing early cancer detection and precision oncology.